ACL
MRNA icon

APEIRON Capital Ltd’s Moderna MRNA Stock Holding History

APEIRON Capital Ltd’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,115
Closed -$1.13M – 14
2024
Q4 		$1.13M Hold
27,115
– – 0.42% 12
2024
Q3 		$1.81M Hold
27,115
– – 0.65% 10
2024
Q2 		$3.22M Buy
27,115
+20,046
+284% +$2.54M 1.12% 10
2024
Q1 		$753K Sell
7,069
-24,131
-77% -$2.43M 0.38% 12
2023
Q4 		$3.1M Buy
31,200
+15,300
+96% +$1.29M 4.56% 7
2023
Q3 		$1.64M Hold
15,900
– – 1.1% 9
2023
Q2 		$1.93M Sell
15,900
-7,100
-31% -$947K 1.17% 13
2023
Q1 		$3.53M Buy
+23,000
New +$3.79M 1.97% 9
2022
Q4 		– Sell
-91,000
Closed -$10.8M – 11
2022
Q3 		$10.8M Hold
91,000
– – 7.17% 5
2022
Q2 		$13M Hold
91,000
– – 7.95% 4
2022
Q1 		$15.7M Hold
91,000
– – 6.93% 6
2021
Q4 		$23.1M Buy
91,000
+3,100
+4% +$906K 6.81% 8
2021
Q3 		$33.8M Buy
87,900
+5,900
+7% +$2.18M 8.88% 5
2021
Q2 		$19.3M Buy
82,000
+47,000
+134% +$8.4M 6.24% 7
2021
Q1 		$4.58M Buy
+35,000
New +$5.07M 1.97% 9

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

APEIRON Capital Ltd's MRNA Position: Q1 2025 in Review

APEIRON Capital Ltd sold out of Moderna (MRNA) in Q1 2025, closing a stake of 27,115 shares — an estimated $1.13M sold.

APEIRON Capital Ltd first reported a position in MRNA in Q1 2021 and held it in 15 quarters. The position peaked at $33.8M in Q3 2021. 694 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • APEIRON Capital Ltd reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • APEIRON Capital Ltd sold 27,115 Moderna shares in Q1 2025, an estimated $1.13M.
  • APEIRON Capital Ltd first reported a position in Moderna in Q1 2021 and held it in 15 quarters.
  • APEIRON Capital Ltd's Moderna position peaked at $33.8M in Q3 2021.
  • 694 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on APEIRON Capital Ltd's 13F filing for Q1 2025, filed 23 Apr 2025.